-+ 0.00%
-+ 0.00%
-+ 0.00%

JADE BIOSCIENCES ANNOUNCES PRECLINICAL DATA CHARACTERIZING JADE301, A POTENTIALLY BEST-IN-CLASS, HALF-LIFE-EXTENDED ANTI-IFN-Β MONOCLONAL ANTIBODY IN DEVELOPMENT FOR DERMATOMYOSITIS, AT EADV 2026

Reuters·09/30/2026 11:02:43